Skip to content

Cancer Health Center

Font Size

Testicular Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview

Testicular cancer is broadly divided into seminoma and nonseminoma for treatment planning because seminomatous types of testicular cancer are more sensitive to radiation therapy and chemotherapy and are less prone to distant metastases. Moreover, nonseminomas may include teratomatous elements, which tend to be resistant to chemotherapy and often require surgery for cure. By definition, pure seminomas do not contain elements of teratoma. Therefore, surgery plays a larger role in the management of nonseminomas than in the management of seminomas. Nonseminomatous testicular tumors include:

  • Embryonal carcinomas.
  • Yolk sac tumors.
  • Choriocarcinomas.
  • Teratomas.
  • Mixed germ cell tumors.

An international germ cell tumor prognostic classification has been developed based on a retrospective analysis of 5,202 patients with metastatic nonseminomatous and 660 patients with metastatic seminomatous germ cell tumors.[1] All patients received treatment with cisplatin- or carboplatin-containing therapy as their first chemotherapy course. The prognostic classification, shown below, was agreed on in 1997 by all major clinical trial groups worldwide. It should be used for reporting clinical trial results of patients with germ cell tumors.

Recommended Related to Cancer

General Information About Renal Cell Cancer

Incidence and Mortality Estimated new cases and deaths from renal cell (kidney and renal pelvis) cancer in the United States in 2013:[1] New cases: 65,150. Deaths: 13,680. Renal cell cancer, also called renal adenocarcinoma, or hypernephroma, can often be cured if it is diagnosed and treated when still localized to the kidney and to the immediately surrounding tissue. The probability of cure is directly related to the stage or degree of tumor dissemination. Even when regional lymphatics...

Read the General Information About Renal Cell Cancer article > >

A meta-analysis of treatment outcomes for patients with advanced nonseminoma suggested that 5-year survival rates have improved for those patients with a poor prognosis during the period of 1989 to 2004.[2] In addition to improved therapy, the improvement seen in these survival rates could be the result of publication bias, changes in patient selection in reported clinical trials, or more sensitive staging methods that could migrate less-advanced stages to more-advanced stage categories (i.e., stage migration).

Good Prognosis

Nonseminoma:

  • Testis/retroperitoneal primary, and
  • No nonpulmonary visceral metastases, and
  • Good markers–all of:
    • Alpha-fetoprotein (AFP) less than 1,000 ng/mL, and
    • Human chorionic gonadotropin (hCG) less than 5,000 IU/mL (1,000 ng/mL), and
    • Lactate dehydrogenase (LDH) less than 1.5 × the upper limit of normal

    56%–61% of nonseminomas

    5-year progression-free survival (PFS) is 89%; 5-year survival is 92%–94%

Seminoma:

  • Any primary site, and
  • No nonpulmonary visceral metastases, and
  • Normal AFP, any hCG, any LDH

    90% of seminomas

    5-year PFS is 82%; 5-year survival is 86%

    1|2
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    A common one in both men and women.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article